摘要
抗体偶联药物(ADC)是一类新型的肿瘤靶向治疗药物,同时,具有高选择性和化疗药物高活性等特点。目前,已有分别针对黏连蛋白-4、肿瘤相关钙信号传感器2和人表皮生长因子受体-2的3种ADC用于晚期膀胱癌的治疗。该文就用于膀胱癌治疗的ADC研究进展进行了综述。
Antibody-drug conjugates(ADCs)are a new class of tumor targeted therapy drugs with high selectivity and activity of chemotherapy drugs.Three antibody-conjugated drugs targeting Nectin-4,TROP-2 and Her2 have been used for the treatment of advanced bladder cancer.This article reviewed the advances in the treatment of bladder cancer with ADCs.
作者
蒋燕
张春霖(综述)
苟欣
邓远忠(审校)
JIANG Yan;ZHANG Chunlin;GOU Xin;DENG Yuanzhong(Department of Urology,The First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China)
出处
《现代医药卫生》
2023年第20期3537-3540,3546,共5页
Journal of Modern Medicine & Health
关键词
抗体偶联药物
膀胱癌
综述
Antibody-drug conjugates
Bladder cancer
Review
